JC virus conversion rates in natalizumab treated patients: the melbourne longitudinal cohort study

Conclusions
In contrast to recently published data from colleagues in France and Germany, in our longitudinal cohort study rates of durable positive JCV seroconversion correlate closely with expected background rates of JCV seroconversion in the general population. In addition, JCV seroconversion and positive serostatus is not increased in patients with prior exposure to immunosuppressive agents. The low seroconversion rates seen after the first year of exposure suggests that less frequent JCV testing of natalizumab treated patients may be safe.

Source: Journal of Neurology, Neurosurgery and Psychiatry - May 8, 2017 Category: Neurosurgery Authors: Dwyer, C., Jokubaitis, V., Baker, J., Haartsen, J., Rath, L., Coleman, J., Fryer, K., Macintyre, J., Cartwright, A., Skibina, O., Macdonell, R., Butler, E., Shuey, N., Butzkueven, H., Kilpatrick, T., Walt, A. v. d. Tags: Abstracts Source Type: research